These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 33028046)

  • 41. Exosomes-based cell-free cancer therapy: a novel strategy for targeted therapy.
    Dutta A
    Immunol Med; 2021 Jun; 44(2):116-123. PubMed ID: 32924880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy.
    Tomasetti M; Lee W; Santarelli L; Neuzil J
    Exp Mol Med; 2017 Jan; 49(1):e285. PubMed ID: 28104913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary Exosomes: The Potential for Biomarker Utility, Intercellular Signaling and Therapeutics in Urological Malignancy.
    Franzen CA; Blackwell RH; Foreman KE; Kuo PC; Flanigan RC; Gupta GN
    J Urol; 2016 May; 195(5):1331-1339. PubMed ID: 26714199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges.
    Kibria G; Ramos EK; Wan Y; Gius DR; Liu H
    Mol Pharm; 2018 Sep; 15(9):3625-3633. PubMed ID: 29771531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer.
    Srivastava A; Babu A; Filant J; Moxley KM; Ruskin R; Dhanasekaran D; Sood AK; McMeekin S; Ramesh R
    J Biomed Nanotechnol; 2016 Jun; 12(6):1159-73. PubMed ID: 27319211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exosomes in tumor microenvironment: novel transporters and biomarkers.
    Wang Z; Chen JQ; Liu JL; Tian L
    J Transl Med; 2016 Oct; 14(1):297. PubMed ID: 27756426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy.
    Crow J; Samuel G; Godwin AK
    Expert Rev Mol Diagn; 2019 Dec; 19(12):1079-1088. PubMed ID: 31687863
    [No Abstract]   [Full Text] [Related]  

  • 48.
    Zeng W; Yin X; Jiang Y; Jin L; Liang W
    STAR Protoc; 2021 Mar; 2(1):100361. PubMed ID: 33786458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies.
    Kwantwi LB
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9487-9503. PubMed ID: 37154928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Communication in tiny packages: Exosomes as means of tumor-stroma communication.
    Daßler-Plenker J; Küttner V; Egeblad M
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188340. PubMed ID: 31926290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Influence of a Stressful Microenvironment on Tumor Exosomes: A Focus on the DNA Cargo.
    Domenis R; Cifù A; Curcio F
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Implications of Exosomes: Targeted Drug Delivery for Cancer Treatment.
    Massey AE; Malik S; Sikander M; Doxtater KA; Tripathi MK; Khan S; Yallapu MM; Jaggi M; Chauhan SC; Hafeez BB
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges.
    Syn NL; Wang L; Chow EK; Lim CT; Goh BC
    Trends Biotechnol; 2017 Jul; 35(7):665-676. PubMed ID: 28365132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exosome-based anticancer vaccines: From Bench to bedside.
    Zhao G; Wang Y; Xing S; Jiang Y; Ding J; Cai Y; Ma P; Miao H; Fang Y; Jiang N; Cui D; Yu Y; Tang Q; Wang S; Li N
    Cancer Lett; 2024 Jul; 595():216989. PubMed ID: 38825162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment.
    Sun Z; Yang S; Zhou Q; Wang G; Song J; Li Z; Zhang Z; Xu J; Xia K; Chang Y; Liu J; Yuan W
    Mol Cancer; 2018 Apr; 17(1):82. PubMed ID: 29678180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exosome-based Tumor Therapy: Opportunities and Challenges.
    Li C; Hou X; Zhang P; Li J; Liu X; Wang Y; Guan Q; Zhou Y
    Curr Drug Metab; 2020; 21(5):339-351. PubMed ID: 32410558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy.
    Roma-Rodrigues C; Raposo LR; Cabral R; Paradinha F; Baptista PV; Fernandes AR
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments.
    Taylor DD; Gercel-Taylor C
    Semin Immunopathol; 2011 Sep; 33(5):441-54. PubMed ID: 21688197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.
    Naseri M; Bozorgmehr M; Zöller M; Ranaei Pirmardan E; Madjd Z
    Oncoimmunology; 2020 Jun; 9(1):1779991. PubMed ID: 32934883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-Isolation of Cytokines and Exosomes: Implications for Immunomodulation Studies.
    Benjamin-Davalos S; Koroleva M; Allen CL; Ernstoff MS; Shu S
    Front Immunol; 2021; 12():638111. PubMed ID: 33968029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.